|
1
|
Posner M and Vermorken JB: Induction
therapy in the modern era of combined-modality therapy for locally
advanced head and neck cancer. Semin Oncol. 35:221–228. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen EE, Lingen MW and Vokes EE: The
expanding role of systemic therapy in head and neck cancer. J Clin
Oncol. 9:1743–1752. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He L and Hannon GJ: MicroRNAs: small RNAs
with a big roll in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pan X, Wang ZX and Wang R: MicroRNA-21: a
novel therapeutic target in human cancer. Cancer Biol Ther.
12:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaur AB, Holbeck SL, Colburn NH and Israel
MA: Down-regulation of Pdcd4 by mir-21 facilitates glioblastoma
pro-liferation in vivo. Neuro Oncol. 13:580–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meng F, Henson R, Wehbe-Janek H, et al:
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene
in human hepatocellular cancer. Gastroenterology. 133:647–658.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gabriely G, Wurdinger T, Kesari S, et al:
MicroRNA 21 promotes glioma invasion by targeting matrix
metalloproteinase regulators. Mol Cell Biol. 28:5369–5380. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rawlings JS, Rosler KM and Harrison DA:
The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He G and Karin M: NF-κB and STAT3 - key
players in liver inflammation and cancer. Cell Res. 21:159–168.
2011.
|
|
10
|
Wang YY, Sun G, Luo H, et al: MiR-21
modulates hTERT through a STAT3-dependent manner on glioblastoma
cell growth. CNS Neurosci Ther. 18:722–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han L, Yue X, Zhou X, et al: MicroRNA-21
expression is regulated by β-catenin/STAT3 pathway and promotes
glioma cell invasion by direct targeting RECK. CNS Neurosci Ther.
18:573–583. 2012.
|
|
12
|
Yang CH, Yue J, Pfeffer SR, et al:
MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma
cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lederle W, Depner S, Schnur S, et al: IL-6
promotes malignant growth of skin SCCs by regulating a network of
autocrine and paracrine cytokines. Int J Cancer. 128:2803–2814.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou X, Ren Y, Moore L, et al:
Downregulation of miR-21 inhibits EGFR pathway and suppresses the
growth of human glioblastoma cells independent of PTEN status. Lab
Invest. 90:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han L, Zhang A, Wang H, et al:
Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small
interference RNA on U251 glioma cells in vitro and in vivo. Hum
Gene Ther. 4:417–426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J, Huang H, Sun L, et al: MiR-21
indicates poor prognosis in tongue squamous cell carcinomas as an
apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu ZW, Zhong LP, Ji T, et al: MicroRNAs
contribute to the chemoresistance of cisplatin in tongue squamous
cell carcinoma lines. Oral Oncol. 46:317–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Parkin DM, Bray F, Ferlay J, et al: Global
cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
19
|
Grandis JR, Drenning SD, Zeng Q, et al:
Constitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci.
97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bourguignon LY, Earle C, Wong G, et al:
Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21
expression and chemoresistance in hyaluronan/CD44-activated head
and neck squamous cell carcinoma cells. Oncogene. 31:149–160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Volinia S, Calin GA, Liu CG, et al: A
micro-RNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu X, Han Y, Wu Y, et al: Prognostic role
of microRNA-21 in various carcinomas: a systematic review and
meta-analysis. Eur J Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sheedy FJ, Palsson-McDermott E, Hennessy
EJ, et al: Negative regulation of TLR4 via targeting of the
proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat
Immunol. 11:141–147. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Löffler D, Brocke-Heidrich K, Pfeifer G,
et al: Interleukin-6 dependent survival of multiple myeloma cells
involves the Stat3-mediated induction of microRNA-21 through a
highly conserved enhancer. Blood. 110:1330–1333. 2007.PubMed/NCBI
|
|
26
|
Horiguchi A, Asano T, Kuroda K, et al:
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell
carcinoma. Br J Cancer. 102:1592–1599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grandis JR, Drenning SD, Chakraborty A, et
al: Requirement of Stat3 but not Stat1 activation for epidermal
growth factor receptor-mediated cell growth in vitro. J Clin
Invest. 102:1385–1392. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johnson DE: Targeting proliferation and
survival pathways in head and neck cancer for therapeutic benefit.
Chin J Cancer. 31:319–326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kotzsch M, Farthmann J, Meye A, et al:
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression
levels in breast cancer. Eur J Cancer. 41:2760–2768. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Göke R, Barth P, Schmidt A, et al:
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction
of p21Waf1/Cip1. Am J Physiol Cell Physiol.
287:C1541–C1546. 2004.PubMed/NCBI
|
